CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.
CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.
Marangoni
E
E
Translational Research Department, Institut Curie, 75010 Paris, France. Elisabetta.Marangoni@curie.fr
Lecomte
N
N
Durand
L
L
de Pinieux
G
G
Decaudin
D
D
Chomienne
C
C
Smadja-Joffe
F
F
Poupon
M-F
MF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D008325:Mammary Neoplasms, Experimental / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; C476399:Cd44 protein, mouse; D018960:Hyaluronan Receptors